Indications for: SEZABY
Neonatal seizures in term and preterm infants.
See full labeling. Give by IV infusion over 15mins into a large peripheral vein. First loading dose: 20mg/kg. If seizures persist or recur after initial loading dose, may give a second loading dose (preterm infants: 10mg/kg or 20mg/kg; term infants: 20mg/kg) no sooner than 15mins after the first loading dose. Max total loading dose: 40mg/kg. Maintenance dose (initiate 8–12hrs after the first loading dose): 4.5mg/kg/day given in 2 or 3 divided doses (1.5mg/kg every 8hrs or 2.25mg/kg every 12hrs) for up to 5 days.
Risks from concomitant use with opioids. Dependence and withdrawal reactions after use of Sezaby for a longer duration than recommended. Abuse, misuse, and addiction with unapproved use in adolescents and adults.
Must be experienced in managing serious cardiorespiratory adverse reactions (including airway management). Dependence and withdrawal reactions. Avoid abrupt cessation if used for a longer duration than recommended; withdraw gradually. Not approved for use in adolescents or adults; unapproved use exposes them to risks of abuse, misuse, and addiction. Monitor for respiratory depression or insufficiency. Discontinue at the 1st sign of a rash, unless not drug related. If serious dermatologic reactions (eg, Stevens-Johnson syndrome [SJS] or toxic epidermal necrolysis [TEN]) signs/symptoms occur, do not resume and consider alternative therapy. Evaluate immediately if signs/symptoms of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or hypersensitivity reactions develop; discontinue if alternative etiology cannot be established. Avoid in those who are at significant risk of developing torsade de pointes (eg, congenital long QT syndrome, uncontrolled or significant cardiac disease, recent MI, HF, unstable angina, bradyarrhythmias, AV block, aortic stenosis, uncontrolled hypothyroidism); if unavoidable, obtain ECGs during treatment, monitor serum electrolytes and correct abnormalities. Avoid perivascular extravasation or intra-arterial injection. Discontinue if infusion site reactions occur. Embryo-fetal toxicity. Neonates exposed through breast milk; monitor.
Increased risk of sedation, respiratory depression, coma, and death with opioids or other CNS depressants; reserve concomitant use in those for whom alternative options are inadequate; limit dosages/durations to minimum required; monitor closely. Avoid concomitant drugs that may increase the QT prolongation risk or drugs that may potentiate phenobarbital; if unavoidable, monitor. Concomitant use with CYP2C9, CYP2C19, CYP2E1, UGT inhibitors or inducers may increase risk of adverse reactions or reduce efficacy; if unavoidable, consider titration and monitor closely. Antagonizes CYP3A, CYP2B6, CYP2C(s), UGTs substrates; if unavoidable, consider increasing substrate dose and monitor closely.
Abnormal respiration, sedation, feeding disorder, hypotension; serious dermatologic reactions (eg, SJS, TEN, DRESS), hypersensitivity reactions, infusion site reactions.
Half-life: ~1 week.
Generic Drug Availability: